- Home
- NSTS vs BMEA Comparison
NSTS vs BMEA Comparison
Compare NSTS & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- BMEA
- Stock Information
- Founded
- NSTS 1921
- BMEA 2017
- Country
- NSTS United States
- BMEA United States
- Employees
- NSTS N/A
- BMEA N/A
- Industry
- NSTS Savings Institutions
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- BMEA Health Care
- Exchange
- NSTS Nasdaq
- BMEA Nasdaq
- Market Cap
- NSTS 65.5M
- BMEA 65.8M
- IPO Year
- NSTS N/A
- BMEA 2021
- Fundamental
- Price
- NSTS $12.33
- BMEA $1.85
- Analyst Decision
- NSTS
- BMEA Strong Buy
- Analyst Count
- NSTS 0
- BMEA 10
- Target Price
- NSTS N/A
- BMEA $22.30
- AVG Volume (30 Days)
- NSTS 4.9K
- BMEA 5.6M
- Earning Date
- NSTS 08-08-2025
- BMEA 07-30-2025
- Dividend Yield
- NSTS N/A
- BMEA N/A
- EPS Growth
- NSTS N/A
- BMEA N/A
- EPS
- NSTS N/A
- BMEA N/A
- Revenue
- NSTS $9,115,000.00
- BMEA N/A
- Revenue This Year
- NSTS N/A
- BMEA N/A
- Revenue Next Year
- NSTS N/A
- BMEA N/A
- P/E Ratio
- NSTS N/A
- BMEA N/A
- Revenue Growth
- NSTS 78.72
- BMEA N/A
- 52 Week Low
- NSTS $9.37
- BMEA $1.29
- 52 Week High
- NSTS $13.32
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- NSTS 55.78
- BMEA 45.95
- Support Level
- NSTS $12.24
- BMEA $1.81
- Resistance Level
- NSTS $12.33
- BMEA $3.08
- Average True Range (ATR)
- NSTS 0.12
- BMEA 0.24
- MACD
- NSTS -0.03
- BMEA -0.07
- Stochastic Oscillator
- NSTS 92.12
- BMEA 15.13
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.